A mGlu2/3 Agonist in the Treatment of PTSD
Phase of Trial: Phase I
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 29 Apr 2016 Status changed from completed to discontinued because principal investigator no longer at NYU. No data was analyzed
- 02 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 26 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.